13F filer · CIK 1697748 ↗
ARK Invest
You are looking at Q3 2017. See the latest, Q2 2026 →
Reported value
$819.3M
+60% on the quarter before
Positions
145
39 new · 3 sold out
Top 10
34.1%
of the value
Est. gain
+$61.7M
on stocks held all quarter
Est. return
+12.5%
on those stocks since Q2 2017
Positions as of Sep 30, 2017, from ARK Invest's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
The 24 largest positions, 61% of the reported value, each sized by its share, colored by what the fund did with it since Q2 2017. Striped tiles are options.
Largest buys
Since Q2 2017, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Bitcoin Investment Trust~$27.8MNew · 0.0% → 3.4%+39,603 shares
- Tencent Holdings Ltd-Uns ADR~$13.1MNew · 0.0% → 1.6%+297,497 shares
- Twitter Inc~$12.0MAdded · 3.2% → 3.4%+713,517 shares
- Softbank Group Corp-Unsp ADR~$10.3MNew · 0.0% → 1.3%+253,041 shares
- Nintendo Co Ltd-Unspons ADR~$9.6MNew · 0.0% → 1.2%+209,891 shares
- Tesla~$8.7MAdded · 2.7% → 2.6%+25,593 shares
- Apple~$7.9MAdded · 0.1% → 1.1%+51,521 shares
- Stratasys Ltd~$7.5MAdded · 5.6% → 4.4%+324,590 shares
- Redfin Corp~$6.7MNew · 0.0% → 0.8%+266,290 shares
- Amazon~$6.3MAdded · 5.6% → 4.3%+6,534 shares
Largest sells
Since Q2 2017, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Kite Pharma Inc~$20.1MCut · 2.3% → 0.0%−112,088 shares
- Qualcomm~$3.8MCut · 0.9% → 0.1%−73,040 shares
- Baidu~$1.8MCut · 3.6% → 2.9%−7,237 shares
- Proto Labs Inc~$856,228Cut · 2.7% → 1.9%−10,663 shares
- IBM~$706,000Sold out · 0.1% → 0.0%−4,588 shares
- Orbital Atk Inc~$650,000Sold out · 0.1% → 0.0%−6,609 shares
- Intuit~$527,577Cut · 0.4% → 0.2%−3,711 shares
- General Electric Co~$428,227Cut · 0.2% → 0.1%−17,718 shares
- AeroVironment~$201,154Cut · 1.1% → 0.9%−3,717 shares
- Du Pont E I De Nemours & Co~$94,000Sold out · 0.0% → 0.0%−1,167 shares
Holdings
As of Sep 30, 2017. Changes are in shares against Jun 30, 2017, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stratasys LtdCommon Stock · shares +26% · price −0.8% | 4.4% | $36.0M | −$234,483 | ||||||||
| AmazonCommon Stock · shares +22% · price −0.7% | 4.3% | $35.0M | −$199,423 | ||||||||
| Athenahealth IncCommon Stock · shares +26% · price −11.5% | 3.7% | $30.4M | −$3.1M | ||||||||
| NvidiaCommon Stock · shares +28% · price +23.7% | 3.5% | $28.9M | +$4.3M | ||||||||
| Bitcoin Investment TrustOpen-End Fund · shares New | 3.4% | $27.8M | — | ||||||||
| Twitter IncCommon Stock · shares +77% · price −5.6% | 3.4% | $27.6M | −$922,089 | ||||||||
| Illumina IncCommon Stock · shares +22% · price +14.8% | 3.1% | $25.2M | +$2.7M | ||||||||
| BaiduADR · shares −7.0% · price +38.5% | 2.9% | $23.7M | +$6.6M | ||||||||
| Juno Therapeutics IncCommon Stock · shares +4.2% · price +50.1% | 2.9% | $23.4M | +$7.5M | ||||||||
| TeslaCommon Stock · shares +68% · price −5.7% | 2.6% | $21.6M | −$775,921 | ||||||||
| Bluebird Bio IncCommon Stock · shares +12% · price +30.7% | 2.3% | $18.5M | +$3.9M | ||||||||
| AlphabetCommon Stock · shares +16% · price +5.5% | 2.2% | $17.7M | +$798,639 | ||||||||
| NetflixCommon Stock · shares +51% · price +21.4% | 2.1% | $17.2M | +$2.0M | ||||||||
| Splunk IncCommon Stock · shares +25% · price +16.8% | 2.0% | $16.8M | +$1.9M | ||||||||
| Editas Medicine IncCommon Stock · shares +35% · price +43.1% | 2.0% | $16.5M | +$3.7M | ||||||||
| 2u IncCommon Stock · shares +23% · price +19.4% | 2.0% | $16.1M | +$2.1M | ||||||||
| Proto Labs IncCommon Stock · shares −5.1% · price +19.4% | 1.9% | $15.8M | +$2.6M | ||||||||
| Xilinx IncCommon Stock · shares +23% · price +10.1% | 1.8% | $15.1M | +$1.1M | ||||||||
| Hortonworks IncCommon Stock · shares +6.6% · price +31.6% | 1.8% | $15.1M | +$3.4M | ||||||||
| SalesforceCommon Stock · shares +43% · price +7.9% | 1.8% | $14.9M | +$758,388 | ||||||||
| MetaCommon Stock · shares +20% · price +13.2% | 1.8% | $14.8M | +$1.4M | ||||||||
| Seres Therapeutics IncCommon Stock · shares +17% · price +41.9% | 1.7% | $14.3M | +$3.6M | ||||||||
| Invitae CorpCommon Stock · shares +49% · price −2.0% | 1.7% | $13.7M | −$187,060 | ||||||||
| Lendingclub CorpCommon Stock · shares +53% · price +10.5% | 1.6% | $13.2M | +$821,801 | ||||||||
| Tencent Holdings Ltd-Uns ADRADR · shares New | 1.6% | $13.1M | — | ||||||||
| Total · 145 positions | 100% | $819.3M | +$61.7M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2017 to Q3 2017: 106 stocks held throughout, up $61.7M (+12.5%).
- Juno Therapeutics Inc+$7.5M+50%
- Baidu+$6.6M+38%
- Nvidia+$4.3M+24%
- Bluebird Bio Inc+$3.9M+31%
- Editas Medicine Inc+$3.7M+43%
- 3d Systems Corp−$526,946−28%
- Organovo Holdings Inc−$592,169−16%
- Tesla−$775,921−6%
- Twitter Inc−$922,089−6%
- Athenahealth Inc−$3.1M−12%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $15.40B+20% | SEC ↗ |
| Q1 2026 | May 12, 2026 | $12.86B−15% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $15.07B−10% | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | $16.80B+23% | SEC ↗ |
| Q2 2025 | Jul 30, 2025 | $13.64B+37% | SEC ↗ |
| Q1 2025 | May 7, 2025 | $9.99B−17% | SEC ↗ |
| Q4 2024 | Feb 4, 2025 | $12.01B+10% | SEC ↗ |
| Q3 2024 | Oct 31, 2024 | $10.93B−3% | SEC ↗ |
| Q2 2024 | Jul 26, 2024 | $11.27B−22% | SEC ↗ |
| Q1 2024 | Apr 18, 2024 | $14.44B−14% | SEC ↗ |
| Q4 2023 | Jan 17, 2024 | $16.89B+29% | SEC ↗ |
| Q3 2023 | Oct 18, 2023 | $13.07B−13% | SEC ↗ |
| Q2 2023 | Jul 10, 2023 | $15.10B+4% | SEC ↗ |
| Q1 2023 | Apr 17, 2023 | $14.55B+26% | SEC ↗ |
| Q4 2022 | Jan 24, 2023 | $11.54B−20% | SEC ↗ |
| Q3 2022 | Oct 17, 2022 | $14.35B−15% | SEC ↗ |
| Q2 2022 | Jul 11, 2022 | $16.91B−29% | SEC ↗ |
| Q1 2022 | Apr 18, 2022 | $23.96B−28% | SEC ↗ |
| Q4 2021 | Jan 28, 2022 | $33.08B−21% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $41.64B−23% | SEC ↗ |
| Q2 2021 | Aug 5, 2021 | $53.74B+7% | SEC ↗ |
| Q1 2021 | May 13, 2021 | $50.34B+34% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $37.59B+123% | SEC ↗ |
| Q3 2020 | Oct 30, 2020 | $16.86B+81% | SEC ↗ |
| Q2 2020 | Aug 11, 2020 | $9.30B+132% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $4.01B+1% | SEC ↗ |
| Q4 2019 | Jan 31, 2020 | $3.96B−13% | SEC ↗ |
| Q3 2019 | Nov 12, 2019 | $4.58B+15% | SEC ↗ |
| Q2 2019 | Jul 30, 2019 | $3.97B+13% | SEC ↗ |
| Q1 2019 | May 13, 2019 | $3.50B+42% | SEC ↗ |
| Q4 2018 | Feb 11, 2019 (amended) | $2.46B−26% | SEC ↗ |
| Q3 2018 | Nov 7, 2018 | $3.31B+21% | SEC ↗ |
| Q2 2018 | Aug 7, 2018 | $2.73B+36% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $2.01B+60% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $1.26B+53% | SEC ↗ |
| Q3 2017 | Nov 9, 2017 | $819.3M+60% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $513.6M+48% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $346.9M+26% | SEC ↗ |
| Q4 2016 | Feb 13, 2017 | $274.9M | SEC ↗ |